EZH2 and mature T-cell and NK-cell non-Hodgkin lymphoma: Inhibition of enhancer of zeste homolog 2 (EZH2) using SHR2554 and inhibition of EZH1/2, enzymatic catalytic subunit of PRC2, using HH2853 have also shown promising outcomes in RR PTCL [48, 49] and are under further investigation.